Ryan Huey, MD, MS (@ryanhuey) ranks #16 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 8 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: BREAKWATER, COMMIT, ABC-HCC. CMS Open Payments lists $14 in 2025 general payments.
At a Glance
- 4 posts naming a trial in 2026
- 4 trials discussed by name
- GI Cancer: US #16 · 8 physicians engaged
- CMS Open Payments lists $14 in 2025 general payments.
This Month
What Ryan Huey, MD, MS has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Ryan Huey, MD, MS
Physicians who reposted Ryan Huey, MD, MS’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #16 | — | 8 | 9 | Full ranking |
Trials Ryan Huey, MD, MS Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| BREAKWATER | 1 | #19 of 22 | Jan 10, 2026 |
| COMMIT | 1 | #12 of 14 | Jan 10, 2026 |
| ABC-HCC | 1 | #7 of 7 | Jan 9, 2026 |
| KEYNOTE-937 | 1 | #9 of 12 | Jan 9, 2026 |
Ryan Huey, MD, MS on BREAKWATER
Dr. @skopetz presents BREAKWATER cohort 3, FOLFIRI +/- encorafenib/cetuximab for mCRC with BRAF V600E mutation. ORR 64% vs 39%. OS not yet mature, prelim HR 0.49 (!) Await mature OS data but FOLFIRI appears to be a backbone to combine in 1L with EC. #GI26 @MDAndersonNews https://t.co/8zMN6XHMUV
Ryan Huey, MD, MS on COMMIT
Dr. Rocha Lima presents COMMIT: atezo vs FOLFOX/atezo/bev for dMMR/MSI-H 1L mCRC. mPFS 24.5 vs 5.3 months (HR 0.439) - mitigation of early progression w/ chemo? Higher risk patients did better with chemo? 9.5% G5 deaths on FOLFOX/bev/atezo (!) #GI26 https://t.co/cBg4sMIlXu
Ryan Huey, MD, MS on ABC-HCC
Dr. Galle presents ABC-HCC, atezo/bev vs TACE in HCC. Time to Failure of Tx Strategy 14.6 vs 9.5 months. More data to come but is systemic therapy superior? #GI26 https://t.co/jWoFeOEp2u
Ryan Huey, MD, MS on KEYNOTE-937
Dr. Chan presents KEYNOTE-937, adjuvant pembro in resected/ablated HCC. No change in RFS or OS. #GI26 https://t.co/XXKE7CDsni
Ryan Huey, MD, MS’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Dr. Wainberg presents INCB161734, KRAS G12D inhibitor with or without chemo for mPDAC. Monotherapy (mostly 3L+) with ORR 37%. In combo arm (1L/2L), early ORR 27%, no patients stopped the study drug, dose intensity of chemo was 75%. #GI26 https://t.co/1IaF6DQhGC
Dr. Jess Paulus shows that GLP-1 use associated with improved overall survival for patients with cancer in a large community oncology cohort. Fascinating data that deserves prospective validation. #ASCO26 https://t.co/9VkjwqMTRy
Industry Payments
CMS Open Payments · 2025 general payments
$14 across 1 payments